New Zealand Pharmaceutical Schedule - November 2021 update

1 November 2021 - The November 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

PHARMAC negotiates deal for a further COVID-19 treatment

31 October 2021 - PHARMAC has negotiated an agreement with Roche to purchase another COVID-19 treatment.  ...

Read more →

Cystic fibrosis medicine added to PHARMAC's options for investment list

27 October 2021 - PHARMAC has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has ...

Read more →

PHARMAC says all patients who meet criteria will get next generation diabetes drugs, despite concerns

20 October 2021 - PHARMAC says it will fund next generation diabetes drugs for all people with the condition who ...

Read more →

Bringing a consumer perspective to clinical advice

19 October 2021 - PHARMAC is making changes to the way its advisory committees work to strengthen the input of ...

Read more →

Where is the PHARMAC Review Panel’s interim report?

12 October 2021 - Patient advocacy groups and clinicians are calling out the PHARMAC Review Panel for failing to get their ...

Read more →

OIA documents prove PHARMAC's independent inquiry is a toothless whitewash

11 October 2021 - Following a damning survey of PHARMAC, National can also reveal documents received under OIA show the ...

Read more →

PHARMAC negotiates deal for molnupiravir to treat COVID-19

11 October 2021 - PHARMAC has negotiated an agreement with supplier MSD to purchase the antiviral molnupiravir.  ...

Read more →

70 percent of Kiwis want Government to give PHARMAC more money - survey

10 October 2021 - New Zealanders have sent a clear message to the Government to fund medicines better or their ...

Read more →

Where has PHARMAC gone?

7 October 2021 - As debate has intensified over the last year or so about the procurement of New Zealand’s ...

Read more →

New Zealand Pharmaceutical Schedule - 1 October 2021

1 October 2021 - The October 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

Covid-19 delta outbreak: major PHARMAC review report delayed by lockdown

22 September 2021 - Act says it is "not good enough" an interim report for a much touted independent PHARMAC ...

Read more →

PHARMAC funds tocilizumab to treat cases of COVID-19

16 September 2021 - PHARMAC is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat ...

Read more →

PHARMAC funds new treatment for rheumatoid arthritis to support people impacted by tocilizumab stock shortage

16 September 2021 - PHARMAC has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, ...

Read more →

Limiting the impact on Kiwis as API leaves the NZ market

14 September 2021 - PHARMAC is working hard to limit the impact on over 1 million Kiwis who currently take ...

Read more →